Emerging Vaccines and Therapies--Analysis of Technological Trends

Table of Contents

• 1. Executive Summary
  • 1. Introduction
    • 1. Introduction to Vaccines
    • 2. An Overview of Current Vaccines Industry
  • 2. Scope and Methodology
    • 1. Scope and Segmentation of the Research Service
    • 2. Methodology
• 2. Emerging Vaccine Technologies
  • 1. DNA Vaccines
    • 1. Introduction
    • 2. Polymer Microspheres for DNA Vaccines (USA)
    • 3. DNA-Based HIV Vaccine in Human Trials (USA)
    • 4. Delivering Genetic Material through Nanorods (USA)
  • 2. Monoclonal Antibodies
    • 1. Monoclonal for GI Cancers (USA)
    • 2. Panel of HGS Monoclonals Block HIV Entry (USA)
  • 3. New Vector Systems
    • 1. Adenoviral Vector for HIV (Netherlands)
    • 2. Liposomal Gene Delivery System (USA)
  • 4. Adjuvants
    • 1. Hybridons Agents Trigger Mucosal Immune Response (USA)
    • 2. Nanotechnology-Based Vaccine Adjuvant (USA)
  • 5. Plant-Based Vaccines
    • 1. Russian HIV Plant-Based Vaccine in Preliminary Stages of Development (Russia)
    • 2. LSBCs Plant-Based HIV and HPV Vaccines in Development (USA)
• 3. Novel Vaccine Delivery Systems
  • 1. Inhalation Delivery
    • 1. Tiny Polymer Spheres Deliver Vaccines Directly to the Lungs (USA)
    • 2. Bi-Directional Nasal Device Delivers Drug on Exhalation (Norway)
    • 3. Dry Powder Inhalers for Consistent and Inexpensive Pulmonary Drug Delivery (USA)
    • 4. Simplifying Nasal Route Vaccine Delivery (Denmark)
  • 2. Needle-Free Injections
    • 1. Aradigms Intraject in Final Stages of Development (USA)
    • 2. DNA Influenza Vaccine with Novel Delivery Technology (UK)
    • 3. Liquid Jet Injection (USA)
  • 3. Transdermal Delivery
    • 1. Transcutaneous Immunization (USA)
    • 2. Ultrasonic Energy for Skin Permeation (USA)
  • 4. Oral Delivery
    • 1. New Oral Anthrax Vaccine in the Development Stage (UK)
    • 2. Development of a New Oral Vaccine against Diphtheria (Sweden)
    • 3. Prospective Oral Vaccine for Cervical Cancer (China)
• 4. Emerging Vaccine Products
  • 1. HIV/AIDS Vaccines
    • 1. HIV Vaccine with Therapore Technology in Phase I Trials (USA)
    • 2. BioVex Dendritic Cell Technology for AIDS Vaccine (UK)
    • 3. Transfection Technology for Mercks HIV Vaccine (USA)
  • 2. Cancer Vaccines
    • 1. P53 Gene Therapeutic Cancer Vaccine (USA)
    • 2. Novel Cancer Vaccine in Phase II Trials (UK)
    • 3. Mologens Autologous Cancer Vaccine Looks Good in Clinical Trials (Germany)
    • 4. Biomira Lung Cancer Vaccine Increases Survival (Canada)
    • 5. Novel Approach against Precancerous Cervical Lesions (France)
    • 6. Therion: Anti-Cancer Vaccines Use Multiple Antigen Genes (USA)
    • 7. GVAX Prostate Cancer Vaccine in Phase III Trials (USA)
    • 8. Genzyme: Vaccine Uses Fused Tumor and Dendritic Cells (USA)
  • 3. Infectious Disease Vaccines
    • 1. GSKs Malaria Vaccine for African Children (USA)
    • 2. TIGR Sequence for Pneumococcus (USA)
    • 3. Chiron Meningococcal B Vaccine for New Zealand (USA)
• 5. Development of New Vaccines--Technology Assesment
  • 1. Trend Analysis
    • 1. Technology Trends
    • 2. Corporate Collaborations (Part I)
    • 3. Corporate Collaborations (Part II)
  • 2. Novel Vaccine Technologies - Drivers and Challenges
    • 1. Drivers
    • 2. Challenges
• 6. Key Contacts and Noteworthy Patents
  • 1. Key Contacts
    • 1. Industry Contacts
    • 2. University Contacts
  • 2. Important Patents
    • 1. Patents (Companies)
    • 2. Patents (Universities)
• 7. Frost & Sullivan 2005 Science and Technology Awards
  • 1. Technology Innovation Award
    • 1. Award Description
    • 2. Award Recipient
  • 2. Excellence in Technology
    • 1. Award Description
    • 2. Award Recipient
  • 3. Excellence in Research
    • 1. Award Description
    • 2. Award Recipient
• 8. Critical Reference Tables
  • 1. Biotech Expenditure
    • 1. Number of Biotech Companies (1999-2006)
    • 2. Government Investment in Biotech R&D (1999-2006)
    • 3. Private Investment in Biotech (1999-2006)
  • 2. Number of Biotech Patents
    • 1. USPTO Biotech Patents (1996-2000)
    • 2. EPO Biotech Patents (1996-2000)
  • 3. HIV Incidence and Mortality
    • 1. HIV Prevalence (1999-2006)
    • 2. AIDS Mortality (1999-2006)
  • 4. Cancer Incidence and Mortality
    • 1. Lung Cancer Incidence (1999-2006)
    • 2. Lung Cancer Mortality (1999-2006)
    • 3. Prostate Cancer Incidence (1999-2006)
    • 4. Prostate Cancer Mortality (1999-2006)
  • 5. Infant Mortality and HIB Immunization
    • 1. Infant Mortality Rate (1999-2006)
    • 2. HIB Immunization (1999-2006)